Lumakras

pharma-news-for-gilead-merck-astellas

Oct 22, 2024

Gilead and Merck Announce Encouraging Phase II Results of Islatravir and Lenacapavir Combo; REGENXBIO Highlights Positive Data from Phase II ABBV-RGX-314 Wet AMD Study at AAO 2024; FDA Greenlights Astellas’ VYLOY for Advanced Gastric and GEJ Cancer Therapy; Merck’s CAPVAXIVE Vaccine Yields Strong Immune Response in Adults Vulnerable to Pneumococcal Disease; FDA Postpones LUMAKRAS Colorectal Cancer Verdict to Early 2025

kras-inhibitors-beyond-g12c

Jan 08, 2024

Unlocking New Avenues in KRAS-Driven Cancer Research Beyond G12C

top-10-oncology-drugs-launches-2023

Feb 24, 2023

Top 10 Expected Oncology Drug Launches in 2023

oncological-drugs-to-be-launch-in-2022

Jan 14, 2022

Most Promising Oncological Drugs Expected to Launch in 2022

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper